Mesoporous Polydopamine Nanotherapeutics for MRI-Guided Cancer Photothermal and Anti-Inflammatory Therapy.
Animals
Magnetic Resonance Imaging
/ methods
Mice
Indoles
/ chemistry
Female
Polymers
/ chemistry
Anti-Inflammatory Agents
/ chemistry
Nanoparticles
/ chemistry
Cell Line, Tumor
Photothermal Therapy
/ methods
Reactive Oxygen Species
/ metabolism
Meloxicam
/ chemistry
Gadolinium
/ chemistry
Humans
Mice, Inbred BALB C
Breast Neoplasms
/ diagnostic imaging
Porosity
Arginine
/ chemistry
anti-inflammatory therapy
cancer therapy
magnetic resonance imaging
mesoporous polydopamine
photothermal therapy
Journal
International journal of nanomedicine
ISSN: 1178-2013
Titre abrégé: Int J Nanomedicine
Pays: New Zealand
ID NLM: 101263847
Informations de publication
Date de publication:
2024
2024
Historique:
received:
11
03
2024
accepted:
12
10
2024
medline:
30
10
2024
pubmed:
30
10
2024
entrez:
30
10
2024
Statut:
epublish
Résumé
As a burgeoning cancer treatment modality, photothermal therapy (PTT) has shown robust anti-tumor effects. However, it still faces numerous challenges, such as triggering an inflammatory response and potentially increasing the risk of cancer recurrence. To address these concerns, integration of PTT with anti-inflammatory therapies presents a promising approach to enhance the efficacy of cancer treatment and meanwhile reduce the risk of recurrence. In this study, Gd The incorporation of Arg doping into MAGM NPs was intended to boost its photothermal conversion efficiency and reactive oxygen species (ROS) scavenging ability. Additionally, synergizing with the anti-inflammatory agent meloxicam (MX) within the nanoparticles aimed to enhance the anti-inflammatory effect following photothermal therapy. Furthermore, gadolinium ions (Gd
Sections du résumé
Background
UNASSIGNED
As a burgeoning cancer treatment modality, photothermal therapy (PTT) has shown robust anti-tumor effects. However, it still faces numerous challenges, such as triggering an inflammatory response and potentially increasing the risk of cancer recurrence. To address these concerns, integration of PTT with anti-inflammatory therapies presents a promising approach to enhance the efficacy of cancer treatment and meanwhile reduce the risk of recurrence.
Methods
UNASSIGNED
In this study, Gd
Results
UNASSIGNED
The incorporation of Arg doping into MAGM NPs was intended to boost its photothermal conversion efficiency and reactive oxygen species (ROS) scavenging ability. Additionally, synergizing with the anti-inflammatory agent meloxicam (MX) within the nanoparticles aimed to enhance the anti-inflammatory effect following photothermal therapy. Furthermore, gadolinium ions (Gd
Identifiants
pubmed: 39474123
doi: 10.2147/IJN.S467419
pii: 467419
pmc: PMC11520923
doi:
Substances chimiques
Indoles
0
Polymers
0
polydopamine
0
Anti-Inflammatory Agents
0
Reactive Oxygen Species
0
Meloxicam
VG2QF83CGL
Gadolinium
AU0V1LM3JT
Arginine
94ZLA3W45F
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
10819-10837Informations de copyright
© 2024 Liu et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests in this work.
Références
Acta Biomater. 2023 Mar 15;159:312-323
pubmed: 36708854
Int J Nanomedicine. 2022 Jun 30;17:2883-2890
pubmed: 35795080
Acta Biomater. 2022 Aug;148:258-270
pubmed: 35724918
J Mater Chem B. 2023 May 17;11(19):4203-4210
pubmed: 37114335
ACS Appl Mater Interfaces. 2023 Jun 7;15(22):26241-26251
pubmed: 37232130
Int J Mol Sci. 2021 Sep 14;22(18):
pubmed: 34576075
Adv Mater. 2021 Jun;33(22):e2008481
pubmed: 33899283
Circ Res. 2018 May 11;122(10):1369-1384
pubmed: 29523554
Langmuir. 2021 Aug 3;37(30):8953-8960
pubmed: 34309391
Int J Mol Med. 2016 Nov;38(5):1319-1326
pubmed: 27666161
Theranostics. 2022 Jan 1;12(1):410-417
pubmed: 34987653
Nanomicro Lett. 2022 Nov 11;14(1):220
pubmed: 36367591
Proc Natl Acad Sci U S A. 2013 Dec 24;110(52):20912-7
pubmed: 24324163
Front Bioeng Biotechnol. 2022 Feb 28;10:821256
pubmed: 35295653
ACS Nano. 2020 Feb 25;14(2):2126-2136
pubmed: 32027121
Bioact Mater. 2022 Mar 16;18:228-241
pubmed: 35387171
ACS Appl Mater Interfaces. 2019 Nov 13;11(45):42671-42679
pubmed: 31663328
Angew Chem Int Ed Engl. 2024 Mar 22;63(13):e202318539
pubmed: 38303647
J Colloid Interface Sci. 2023 Dec 15;652(Pt B):1108-1116
pubmed: 37657211
Int J Mol Sci. 2023 Aug 27;24(17):
pubmed: 37686114
ACS Nano. 2014 Apr 22;8(4):3393-401
pubmed: 24673493
Theranostics. 2020 Apr 6;10(11):4997-5010
pubmed: 32308764
Biomaterials. 2023 Apr;295:122030
pubmed: 36758340
Theranostics. 2019 Apr 13;9(10):2843-2855
pubmed: 31244927
Adv Mater. 2021 Jun;33(23):e1906539
pubmed: 32495404
Adv Sci (Weinh). 2022 Apr;9(10):e2105783
pubmed: 35119216
J Nanobiotechnology. 2022 Jul 30;20(1):350
pubmed: 35908057
Lasers Surg Med. 2015 Jul;47(5):452-61
pubmed: 26052931
J Nanobiotechnology. 2021 Nov 17;19(1):365
pubmed: 34789274
APL Bioeng. 2022 Apr 21;6(2):026101
pubmed: 35496642
Cell Prolif. 2021 Nov;54(11):e13130
pubmed: 34599546
Biomaterials. 2022 Aug;287:121621
pubmed: 35704964
Nat Commun. 2022 Apr 14;13(1):1994
pubmed: 35422068
Environ Res. 2023 Nov 15;237(Pt 2):117027
pubmed: 37659647
Small. 2022 Apr;18(13):e2107071
pubmed: 35128798
Adv Mater. 2019 Feb;31(5):e1805936
pubmed: 30537012
Am J Physiol Endocrinol Metab. 2017 Mar 1;312(3):E183-E189
pubmed: 28049625
Angew Chem Int Ed Engl. 2018 Jan 2;57(1):177-181
pubmed: 29125675